Auspex upsizes IPO, adds shares; Concert outlines plans to raise $75M from IPO;

@FierceBiotech: Eisai readies applications for thyroid cancer drug after SFJ delivers PhIII success. More | Follow @FierceBiotech

@JohnCFierce: Furiex preps for buyout talks after IBS drug looks promising in PhIII. News | Follow @JohnCFierce

@DamianFierce: Big Pharma superteam joins NIH to share data, discover new drugs. Story | Follow @DamianFierce

@EmilyMFierce: Mechanism that boosts bone growth could aid osteoporosis drug design. Article via FierceBiotech Research | Follow @EmilyMFierce

> San Diego-based Auspex Pharmaceuticals is upsizing its IPO and now plans to sell 6 million shares at a range of $10 to $12 a share. Report

> Concert Pharmaceuticals set terms for its $75 million IPO, outlining plans to sell 5 million shares at $14 to $16 each. Report

> Amarantus Bioscience announced "positive" clinical data for eltoprazine in a Phase IIa clinical study of adult attention deficit hyperactivity disorder. Release

Medical Device News

@FierceMedDev: FDA: Kids with diabetes can use DexCom's continuous glucose monitor. Story | Follow @FierceMedDev

@MarkHFierce: Here's my perspective, as a patient, on the pacemaker industry. Editor's corner | Follow @MarkHFierce

@MichaelGFierce: Lupin stakes a claim on the sterile injectables market. News | Follow @MichaelGFierce

@EmilyWFierce: Endo waves goodbye to HealthTronics for $130M. Report | Follow @EmilyWFierce

> Boston Scientific appears to turn a corner as sales growth gains momentum. More

> Thermo Fisher closes $13.6B Life Tech acquisition. Item

Pharma News

@FiercePharma: Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices. Story | Follow @FiercePharma

@TracyStaton: From FiercePharmaMarketing: UCB nabs Asian marketing rights to hot Biogen MS drugs. More | Follow @TracyStaton

@EricPFierce: My colleague Mark Hollmer offers a thoughtful analysis of pacemakers after having one put in. Check it out. Item | Follow @EricPFierce

@CarlyHFierce: More Humira sales gains help AbbVie meet forecasts. News | Follow @CarlyHFierce

> Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices. More

> Bayer, Roche and GSK cancer meds win nod for special U.K. funding. News

> GlaxoSmithKline's Advair loses share to AstraZeneca's aggressive Symbicort discounts. Story

Biotech Research News

> $40M gift from stem cell agency will fund new genomics initiative. Item

> Exposure to acid turns adult cells into stem cells. More

> Merck halts drug testing on chimpanzees. News

> Mechanism that boosts bone growth could aid osteoporosis drug design. Report

> Stem cell signaling protein spurs cancer spread. Story

> Epilepsy drug reverses fatty liver disease in obese mice. Article

Pharma Manufacturing News

> Daiichi Sankyo is bringing the hammer down on Ranbaxy. More

> Amgen is halting Epogen manufacturing in Colorado. Story

> Abbott is closing a plant in Puerto Rico as Mexico's Neolpharma expands. Article

> Alexion buys vial-filling facility in Ireland. News

> Lupin stakes a claim on the sterile injectables market. Report

> Sources: Recipharm looks at doing an IPO to expand cash. Item

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.